Allakos price target lowered to $1 from $1.50 at Barclays

Barclays lowered the firm’s price target on Allakos to $1 from $1.50 and keeps an Underweight rating on the shares. The company is restructuring following the “unsurprising” lirentelimab failures, the analyst tells investors in a research note.